An observational study in Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer (GC) and Hepatocellular Carcinoma (HCC), sponsored by Peking University Cancer Hospital & Institute. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Peking University Cancer Hospital & Institute · Observational
Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.
Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 31st largest by planned enrollment of the 50 observational ones that give a count, is one of 48 that started in 2026, is one of 50 observational ones, reaches primary completion later than 186 of the 212 other live ones, and was the 401st registered.
675 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
401 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 239 · Phase 3 62 · Phase 4 1
First in 1999; this study’s year is marked. 48 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 247 across 86 observational studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 70 across the 351 interventional studies, 205 across the 50 observational. Of the 92 that completed or were terminated, 11 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 401 have an industry lead sponsor. The 10 most frequent:
Peking University Cancer Hospital & Institute is the lead sponsor of 269 studies on the registry; 128 are open to participants now.
Peking University Cancer Hospital & Institute has 9 studies filed under Esophageal Squamous Cell Carcinoma — fewer than ten, so there is no comparison to draw.
45 of the studies in Esophageal Squamous Cell Carcinoma with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06194734Phase 3Beijing Konruns Pharmaceutical Co., Ltd.A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | 2026-12-30 |
| NCT06907602Phase 3Peking Union Medical College HospitalOptimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma | 2026-12-31 |
| NCT04848753Phase 3Shanghai Junshi Bioscience Co., Ltd.Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 2027-05-12 |
| NCT04550260Phase 3AstraZenecaStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | 2027-06-30 |
| NCT07016737Phase 3Ye jinjunImmunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy | 2027-09-01 |
Add all 45 to your calendar (.ics) → With an account.
Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Psoralea corylifolia (Buguzhi) is a traditional Chinese medicine (TCM) herb with reported anti-tumor activity; its major bioactive compound, isobavachalcone (IBC), has been shown to inhibit ADORA3 and the downstream FAK/AKT/NF-κB signaling axis in gastrointestinal cancers. This is a retrospective, single-arm observational study reviewing medical records of approximately 120 patients with gastrointestinal cancers (esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, and colorectal cancer; n=30 each) treated at Peking University Cancer Hospital who received TCM formulas containing Psoralea corylifolia as part of routine clinical care. The study evaluates changes in tumor response assessed by RECIST version 1.1 and in Karnofsky Performance Status (KPS) between baseline and 8-12 weeks after initiation of treatment.
Background: ADORA3 (adenosine receptor A3) is upregulated in several gastrointestinal cancers and correlates with poor prognosis. Isobavachalcone (IBC), a major bioactive chalcone isolated from Psoralea corylifolia, directly binds ADORA3, blocks intracellular Ca²⁺ mobilization, disrupts the calmodulin/focal adhesion kinase (FAK) complex, and inhibits FAK/AKT/NF-κB signaling, thereby suppressing oncogenic signaling and reprogramming the tumor immune microenvironment.
Study design and population: This is a retrospective, single-arm, case-series observational study reviewing medical records of patients with histologically confirmed gastrointestinal cancers (esophageal squamous cell carcinoma [ESCC], gastric cancer [GC], hepatocellular carcinoma [HCC], or colorectal cancer [CRC]) treated at Peking University Cancer Hospital who received TCM formulas containing Psoralea corylifolia (Buguzhi) as part of routine clinical care. Approximately 120 patients (30 per cancer type) with available baseline and post-treatment imaging and performance status records will be included.
Outcomes: The primary outcomes are (1) tumor response assessed by contrast-enhanced CT or MRI according to RECIST version 1.1 (CR/PR/SD/PD) and (2) change in Karnofsky Performance Status (KPS) score (improvement or deterioration defined as a change of ≥10 points), both measured at baseline and at 8-12 weeks after initiation of Buguzhi-containing TCM treatment.
Analysis and limitations: Concurrent anti-cancer treatments (e.g., chemotherapy, radiotherapy, targeted therapy, immunotherapy) will be recorded and described, and exploratory subgroup analyses will be performed by cancer type and concurrent treatment. As a single-arm retrospective study without a control group, observed changes cannot be definitively attributed to Buguzhi-containing TCM formulas, and results will be interpreted as hypothesis-generating real-world evidence.
Patients with histologically confirmed gastrointestinal cancers (esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, or colorectal cancer) treated at Peking University Cancer Hospital, who received Psoralea corylifolia-containing TCM formulas as part of routine clinical care, and have available imaging and clinical follow-up data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with gastrointestinal cancers (esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), hepatocellular carcinoma (HCC), and colorectal cancer (CRC)) who received TCM formulas containing Psoralea corylifolia (Buguzhi) as part of routine clinical care.
Other: Psoralea corylifolia-Containing TCM Formula
Traditional Chinese Medicine herbal formula containing Psoralea corylifolia (Buguzhi), prescribed as part of routine clinical care for gastrointestinal cancers patients.
Tumor response evaluation
Tumor response will be assessed by contrast-enhanced CT or MRI according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients will be classified into four categories: Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD).
Time frame: Baseline and at 8-12 weeks after initiation of TCM formula containing Psoralea corylifolia (Buguzhi) treatment
Karnofsky Performance Status (KPS) Score Change
Changes in Karnofsky Performance Status (KPS) score will be assessed at baseline and after treatment. KPS score ranges from 0 (death) to 100 (normal, no complaints). Improvement is defined as an increase of ≥10 points; deterioration is defined as a decrease of ≥10 points.
Time frame: Baseline and at 8-12 weeks after initiation of TCM formula containing Psoralea corylifolia (Buguzhi) treatment
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal Squamous Cell Carcinoma →
Peking University Cancer Hospital & Institute →